An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.

ABSTRACT: Glioblastoma multiforme (GBM) is the most aggressive and common malignant primary brain tumor. Patients with GBM often have poor prognoses, with a median survival of ∼15 months. Enhanced understanding of the molecular biology of central nervous system tumors has led to modifications in their classifications, the most recent of which classified these tumors into new categories and made some changes in their nomenclature and grading system. This review aims to give a panoramic view of the last 3 years' findings in glioblastoma characterization, its heterogeneity, and current advances in its treatment. Several molecular parameters have been used to achieve an accurate and personalized characterization of glioblastoma in patients, including epigenetic, genetic, transcriptomic and metabolic fea

SUBMITTER: Verdugo E 

PROVIDER: S-EPMC9648390 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature